SABS · SAB Biotherapeutics, Inc. · Debt

$2.88 +0.28 (+10.77%) At close · Oct 20

Market Cap

$236.56M

90.99M

Volume · Oct 20 814.54K Avg daily vol (3M) 534.24K

Debt Profile

Completed filing coverage through Mar 24, 2023

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Finance lease liabilities	2026-06-30	USD 3,200,000	10-Q filed 2026-08-06
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current finance lease liabilities USD 160,000 Noncurrent finance lease liabilities USD 3,040,000
Operating lease liabilities	2026-06-30	USD 1,932,000	10-Q filed 2026-08-06
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 481,000 Noncurrent operating lease liabilities USD 1,451,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1833214 CUSIP 78397T202 13F (30d) 4 filings 4 filers Visit website Investor relations